AUTHORS
Henry Castellani, MD, Rina Welkie, MPH2, David Bond, MD, BS3, Sherraine Della-Moretta, MD4, Eric Kraut, MD5, Jennifer E Vaughn, MD, MSPH6, Tzu-Fei Wang, MD7, Jennifer A. Woyach, MD8, Kerry A. Rogers, MD9
AFFILIATIONS
1 The Ohio State University Medical Center, Columbus, Ohio, United States
2 The Ohio State University Medical Center, Columbus, Ohio, United States
3 The Ohio State University Medical Center, Columbus, Ohio, United States
4 The Ohio State University Medical Center, Columbus, Ohio, United States
5 The Ohio State University Medical Center, Columbus, Ohio, United States
6 The Ohio State University Medical Center, Columbus, Ohio, United States
7 Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
8 The Ohio State University Medical Center, Columbus, Ohio, United States
9 The Ohio State University Medical Center, Columbus, Ohio, United States
ABSTRACT
Background
Warm autoimmune hemolytic anemia (wAIHA) is an IgG antibody mediated condition treated with immunosuppression. Corticosteroids and rituximab typically induce initial response, but subsequent therapies are frequently needed for treatment failures, relapses, or intolerable side effects. Therapies for relapsed wAIHA include splenectomy and oral immunosuppressants such as mycophenolate mofetil (MMF). MMF has shown promise in several case series of less than 10 patients (Kotb et al, 2005). It has also shown promise in combination with steroids as front line therapy; Complete Response (CR) was observed in 20/20 patients by week 12 and 90% were relapse free at 14 month follow up (Ghose et al, 2025). Mechanistically, MMF exerts a cytostatic effect on activated B and T lymphocytes and has been suggested to inhibit the primary antibody response, which are useful effects in wAIHA (Allison and Eugui, 1993). We expand on the efficacy and safety data of MMF by performing a retrospective cohort study of patients treated at our institution.
Methods
We performed a retrospective cohort study of 22 patients with wAIHA who were treated with MMF at The Ohio State University Medical Center between October 2011 and April 2025. The primary endpoint was overall response rate (ORR) at 12 weeks after MMF initiation which included complete response (CR), defined as no transfusions in the prior 6 weeks, a hemoglobin above 10 g/dL, and normal hemolytic indices, or partial response (PR), defined as a decrease in transfusions, a 2 g/dL increase in hemoglobin, and improvement in hemolytic indices in the 12 weeks after treatment initiation. Improvement of hemolytic indices was defined as: haptoglobin within 1.5x the lower limit of normal, total bilirubin within 1.5x upper limit of normal, and LDH within 1.5x upper limit of normal. Secondary endpoints included CR and PR rates individually, overall survival (OS) at one-year, adverse events and changes in hemoglobin and corticosteroid dosages after 12 weeks of MMF.
Response rates were summarized as proportions with 95% exact (Clopper-Pearson) confidence intervals (95% CI). Changes between baseline and 12-week hemoglobin and steroid dose were analyzed using Wilcoxon signed-rank test. OS was estimated by the Kaplan-Meier method.
Results
A total of 22 patients with wAIHA treated with MMF were included. Median age was 66 (18, 88), 11 (50%) were female, 6 (27.3%) had an associated autoimmune disease, and 7 (31.3%) had a hematologic malignancy. A total of 16 patients (72.7%) had positive direct antiglobulin tests (DAT); 7 were IgG+ only, and 9 were IgG+ and C3+; the remaining 6 (27.3%) were DAT negative. All but one patient had been treated with steroids prior to MMF; 18 (82%) were on steroids at the time of MMF start. The median number of prior therapies was 2: most commonly steroids (95.4%) and rituximab (68.2%).
ORR was 63.6% (14/22, 95% CI 40.7-82.8), with 4 achieving CR (18.2%) and 10 achieving PR (45.5%) by 12 weeks. The median time to first response was 26 days (6, 210). Median hemoglobin increased from 8.9 g/dL at MMF initiation to 10.9 g/dL at 12 weeks, which was a statistically significant increase (p<0.0001). Of the 18 patients taking steroids when started on MMF, 13 (72%) decreased their daily dose, 4 (22%) remained on the same dose, and only 1 (6%) increased their dose at 12 weeks. The median steroid dose prior to MMF was 20 mg of oral prednisone equivalents daily. After 12 weeks the median decreased to 10 mg; this was a statistically significant decrease (p=0.0007). Estimated one year OS was 85%. MMF was well tolerated. The most common side effect was gastrointestinal upset (23%), followed by worsening cytopenias (9%); one patient experienced clinically significant neutropenia prompting cessation.
Discussion
We present the results of a relatively larger retrospective cohort of patients with wAIHA treated with MMF. We found MMF to be a valuable treatment option with an observed ORR of 63.6% and statistically significant increase in hemoglobin concentration after 12 weeks of therapy. MMF was also associated with a statistically significant decrease in daily corticosteroid dosage. These are clinically meaningful endpoints that may reduce treatment-related morbidity of wAIHA. Building from this, future studies should aim to clarify the duration of effect of MMF, and features associated with favorable response.
DISCLOSURES
Henry Castellani, MD: No relevant conflicts of interest to declare.